Novel Hsp90 inhibitor shows activity in slowing KRAS-mutant NSCLC tumor cell growth. Use with traditional chemotherapy resulted in increased cancer cell death. Phase 2b/3 trial combined with docetaxel under way. SAN DIEGO — The investigational drug ganetespib, a synthetic second-generation Hsp90...
Posted to
News
by
AACR News
on
Tue, Jan 10 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, genetics, KRAS, non-small cell lung cancer, AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, International Association for the Study of Lung Cancer, IASLC, NSCLC, Jaime Acquaviva, David A. Proia, ganetespib, clinical trials, Hsp90 inhibitor
Survival rates were “unsatisfactory” in patients with NSCLC and a KRAS mutation. “Great need” exists for new treatment combinations in this patient population. SAN DIEGO — Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but...
Posted to
News
by
AACR News
on
Mon, Jan 9 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, sorafenib, KRAS, non-small cell lung cancer, AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, International Association for the Study of Lung Cancer, IASLC, NSCLC, Wouter W. Mellema